AR101280A1 - Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial - Google Patents
Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicialInfo
- Publication number
- AR101280A1 AR101280A1 ARP150102330A ARP150102330A AR101280A1 AR 101280 A1 AR101280 A1 AR 101280A1 AR P150102330 A ARP150102330 A AR P150102330A AR P150102330 A ARP150102330 A AR P150102330A AR 101280 A1 AR101280 A1 AR 101280A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- independently
- group
- pyrimidine
- Prior art date
Links
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical compound C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 title abstract 3
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 150000001721 carbon Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 thieno [3,2-d] pyrimidine compound Chemical class 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 1
- 229910003204 NH2 Inorganic materials 0.000 abstract 1
- 229910017711 NHRa Inorganic materials 0.000 abstract 1
- 241000711904 Pneumoviridae Species 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se proveen aquí formulaciones, métodos y compuestos de tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina, y pirrolo[3,2-d]pirimidina sustituidos de fórmula (1) para el tratamiento de infecciones por virus de Pneumovirinae, incluyendo infecciones por virus sincicial respiratorias, así como métodos e intermediarios para la síntesis del compuesto de tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina, y pirrolo[3,2-d]pirimidina sustituidos. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: X es seleccionado del grupo de O, S, NH, o N(C₁₋₆ alquilo); R¹ es seleccionado del grupo de H, CH₃, F, Cl, y NH₂; R² es seleccionado del grupo de F, Cl, ORᵃ, NHRᵃ, CN y N₃; R³ es seleccionado del grupo de CN, ORᵃ, C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -CH₂-O-C₁₋₆ alquilo, -CH₂-S-C₁₋₆ alquilo, C₃₋₄ cicloalquilo, azido, halógeno, C₁₋₃ haloalquilo, SRᵃ, -CH₂-C₃₋₄ cicloalquilo, -O-C₃₋₄ cicloalquilo, y -O-C₁₋₃ haloalquilo; o cuando R² es ORᵃ, los dos grupos ORᵃ en las posiciones 2 y 3 juntos pueden formar con el anillo furanilo al cual están enlazados una estructura seleccionada del grupo de fórmulas (2); R⁴ es seleccionado del grupo de H, -C(=O)R⁶, -C(=O)OR⁶, y -C(=O)NR⁶R⁷; o R⁴ es un grupo de la fórmula (3); en donde: cada Y es O, S, NR, ⁺N(O)(R), N(OR), ⁺N(O)(OR), o N-NR²; y W¹ y W², cuando se toman juntos son -Y³(C(Rʸ)₂)₃Y³-; o uno de W¹ o W² junto con el grupo 3 hidroxi es -Y³- y el otro de W¹ o W² es la fórmula (4); o W¹ y W² son cada uno, independientemente, un grupo de la fórmula (4), en donde: cada Y¹ es, independientemente, O, S, NR, ⁺N(O)(R), N(OR), ⁺N(O)(OR), o N-NR²; cada Y² es independientemente un enlace, O, CR₂, -O-CR₂-, NR, ⁺N(O)(R), N(OR), ⁺N(O)(OR), N-NR², S, S-S, S(O), o S(O)₂; cada Y³ es independientemente O, S, o NR; M1 es 0, 1, 2, ó 3; cada Rˣ es independientemente Rʸ o la fórmula (5) en donde: cada M2a, M2b, y M2c es independientemente 0 ó 1; M2d es 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ó 12; cada Rʸ es independientemente H, F, Cl, Br, I, OH, R, -C(=Y¹)R, -C(=Y¹)OR, -C(=Y¹)N(R)₂, -N(R)₂, -⁺N(R)₃, -SR, -S(O)R, -S(O)₂R, -S(O)(OR), -S(O)₂(OR), -OC(=Y¹)R, -OC(=Y¹)OR, -OC(=Y¹)(N(R)₂), -SC(=Y¹)R, -SC(=Y¹)OR, -SC(=Y¹)(N(R)₂), -N(R)C(=Y¹)R, -N(R)C(=Y¹)OR, -N(R)C(=Y¹)N(R)₂, -SO₂NR², -CN, -N₃, -NO₂, -OR, o W³; o cuando se toman juntos, dos Rʸs sobre el mismo átomo de carbono forman un anillo carbocíclico que tiene 3, 4, 5, 6, ó 7 átomos de carbono de anillo; o cuando se toman juntos, dos Rʸs sobre el mismo átomo de carbono forman junto con el átomo de carbono un heterociclo que tiene 3, 4, 5, 6, ó 7 átomos de anillo en donde un átomo de anillo es seleccionado de O ó N y todos los demás átomos de anillo son carbono; cada R es independientemente H, C₁₋₈ alquilo, C₁₋₈ alquilo sustituido, C₂₋₈ alquenilo, C₂₋₈ alquenilo sustituido, C₂₋₈ alquinilo, C₂₋₈ alquinilo sustituido, C₆₋₁₀ arilo, C₆₋₁₀ arilo sustituido, un heterociclo de 3 a 10 miembros, un heterociclo sustituido de 3 a 10 miembros, un heteroarilo de 5 a 12 miembros, un heteroarilo sustituido de 5 a 12 miembros, arilalquilo, arilaquilo sustituido, heteroarilalquilo, o heteroarilalquilo sustituido; y W³ es W⁴ o W⁵; W⁴ es R, -C(Y¹)Rʸ, -C(Y¹)W⁵, -SO₂Rʸ, o -SO₂W⁵; W⁵ es seleccionado de fenilo, naftilo, un carbociclo C₃₋₈, o un heterociclo de 3 a 10 miembros, en donde W⁵ es independientemente sustituido con grupos 0, 1, 2, 3, 4, 5, ó 6 Rʸ; cada R⁶ y R⁷ es independientemente H, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₄₋₈ carbociclilalquilo, C₆₋₁₀ arilo, C₆₋₁₀ arilo sustituido, heteroarilo de 5 a 10 miembros, heteroarilo de 5 a 10 miembros sustituido, -C(=O)C₁₋₈ alquilo, -S(O)ₙ-C₁₋₈ alquilo o aril-C₁₋₈ alquilo; o R⁶ y R⁷ tomados juntos con un nitrógeno al cual están ambos unidos forman un heterociclo de 3 a 7 miembros en donde cualquier átomo de carbono de anillo de dicho heterociclo puede ser reemplazado opcionalmente con -O-, -S- o -NRᵃ-; y en donde cada C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo o aril-C₁₋₈ alquilo de cada R⁶ o R⁷ es, independientemente, sustituido opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados de halo, hidroxi, CN, N₃, N(Rᵃ)₂ u ORᵃ; y en donde uno, dos o tres de los átomos de carbono no terminales de cada dicho C₁₋₈ alquilo puede ser reemplazado opcionalmente con -O-, -S- o -NRᵃ-; o R⁴ es un grupo seleccionado de los compuestos de fórmula (6) y (7), en donde: R⁸ es seleccionado de fenilo, 1-naftilo, 2-naftilo, el resto de fórmula (8) o el resto de fórmula (9); R⁹ es seleccionado de H y CH₃; R¹⁰ es seleccionado de H o C₁₋₆ alquilo; y R¹¹ es seleccionado de H, C₁₋₈ alquilo, bencilo, C₃₋₆ cicloalquilo, y CH₂-C₃₋₆ cicloalquilo; o R⁴ y el grupo 3 hidroxi se combina para formar la estructura seleccionada de las fórmulas (10) y (11).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029896P | 2014-07-28 | 2014-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101280A1 true AR101280A1 (es) | 2016-12-07 |
Family
ID=53765598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102330A AR101280A1 (es) | 2014-07-28 | 2015-07-22 | Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9828388B2 (es) |
| EP (3) | EP3174870B1 (es) |
| JP (3) | JP2017523169A (es) |
| KR (1) | KR102460181B1 (es) |
| CN (1) | CN106573939B (es) |
| AR (1) | AR101280A1 (es) |
| AU (1) | AU2015298207C1 (es) |
| BR (1) | BR112017001565A2 (es) |
| CA (1) | CA2956571C (es) |
| EA (1) | EA032490B1 (es) |
| ES (2) | ES2910382T3 (es) |
| IL (1) | IL249706A0 (es) |
| MX (1) | MX2017001284A (es) |
| NZ (1) | NZ727996A (es) |
| PL (2) | PL3693367T3 (es) |
| PT (2) | PT3174870T (es) |
| SG (1) | SG11201700213SA (es) |
| SI (2) | SI3174870T1 (es) |
| TW (1) | TWI678369B (es) |
| WO (1) | WO2016018697A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
| HUE060259T2 (hu) | 2015-07-22 | 2023-02-28 | Enanta Pharm Inc | Benzodiazepin származékok mint RSV-gátlók |
| WO2017075590A2 (en) * | 2015-10-30 | 2017-05-04 | Cocrystal Pharma, Inc. | Processes for preparing 2-dihalo ribolactones |
| CA3048729C (en) * | 2017-01-26 | 2023-01-03 | Youla S. Tsantrizos | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof |
| BR112020006334A2 (pt) * | 2017-09-29 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | combinação de agentes farmacêuticos como inibidores de rsv |
| KR102248165B1 (ko) | 2017-12-07 | 2021-05-06 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| KR20210138684A (ko) | 2019-03-18 | 2021-11-19 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 벤조디아제핀 유도체 |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| CN118598916A (zh) | 2020-02-18 | 2024-09-06 | 吉利德科学公司 | 抗病毒化合物 |
| TW202245800A (zh) | 2020-02-18 | 2022-12-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111548384B (zh) * | 2020-03-29 | 2021-04-27 | 常州安蒂卫生物科技有限公司 | 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US135A (en) | 1837-03-03 | Jesse j | ||
| US5458A (en) | 1848-02-22 | Bench-vise | ||
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (es) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4584369A (en) * | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| JP3230056B2 (ja) | 1991-07-02 | 2001-11-19 | インヘイル・インコーポレーテッド | 薬剤のエーロゾル化服用量を形成する装置 |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| CN1968605A (zh) * | 2004-06-15 | 2007-05-23 | 默克公司 | 作为rna依赖性rna病毒聚合酶抑制剂的c－嘌呤核苷类似物 |
| US8133870B2 (en) * | 2004-10-29 | 2012-03-13 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| CN101675053B (zh) | 2006-12-07 | 2014-03-12 | 健泰科生物技术公司 | 磷酸肌醇3-激酶抑制剂化合物及使用方法 |
| NZ598927A (en) | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| ES2393038T3 (es) * | 2007-05-10 | 2012-12-18 | Biocryst Pharmaceuticals, Inc. | Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| SI2937350T1 (en) * | 2008-04-23 | 2018-05-31 | Gilead Sciences, Inc. | 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US10023600B2 (en) | 2009-09-21 | 2018-07-17 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs |
| RS55699B1 (sr) | 2009-09-21 | 2017-07-31 | Gilead Sciences | 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| EP2805960A1 (en) | 2010-07-19 | 2014-11-26 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| CN102351931B (zh) * | 2010-09-07 | 2014-01-22 | 河南省科学院高新技术研究中心 | 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用 |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| CA2807496C (en) * | 2010-09-20 | 2019-01-22 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| RU2599013C2 (ru) | 2010-10-15 | 2016-10-10 | БАЙОКРИСТ ФАРМАСЬЮТИКАЛЗ, ИНК. (э ЮЭс корпорейшн) | Способы и композиции для ингибирования полимеразы |
| NZ613370A (en) | 2010-12-20 | 2015-05-29 | Gilead Sciences Inc | Combinations for treating hcv |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| CN103748098B (zh) * | 2011-10-11 | 2016-06-29 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗或预防呼吸道合胞病毒疾病的化合物 |
| US9073960B2 (en) | 2011-12-22 | 2015-07-07 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA201791916A1 (ru) | 2012-03-13 | 2018-07-31 | Джилид Сайэнс, Инк. | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения |
| GEP201706721B (en) * | 2012-03-21 | 2017-08-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
-
2015
- 2015-07-08 TW TW104122181A patent/TWI678369B/zh active
- 2015-07-22 AU AU2015298207A patent/AU2015298207C1/en active Active
- 2015-07-22 PT PT157450834T patent/PT3174870T/pt unknown
- 2015-07-22 SG SG11201700213SA patent/SG11201700213SA/en unknown
- 2015-07-22 EA EA201790146A patent/EA032490B1/ru not_active IP Right Cessation
- 2015-07-22 ES ES20166438T patent/ES2910382T3/es active Active
- 2015-07-22 US US14/806,227 patent/US9828388B2/en active Active
- 2015-07-22 PL PL20166438T patent/PL3693367T3/pl unknown
- 2015-07-22 JP JP2017502192A patent/JP2017523169A/ja not_active Withdrawn
- 2015-07-22 EP EP15745083.4A patent/EP3174870B1/en active Active
- 2015-07-22 AR ARP150102330A patent/AR101280A1/es unknown
- 2015-07-22 PT PT201664380T patent/PT3693367T/pt unknown
- 2015-07-22 SI SI201531250T patent/SI3174870T1/sl unknown
- 2015-07-22 ES ES15745083T patent/ES2802175T3/es active Active
- 2015-07-22 CA CA2956571A patent/CA2956571C/en active Active
- 2015-07-22 MX MX2017001284A patent/MX2017001284A/es unknown
- 2015-07-22 PL PL15745083T patent/PL3174870T3/pl unknown
- 2015-07-22 SI SI201531826T patent/SI3693367T1/sl unknown
- 2015-07-22 WO PCT/US2015/041574 patent/WO2016018697A1/en active Application Filing
- 2015-07-22 EP EP20166438.0A patent/EP3693367B1/en active Active
- 2015-07-22 NZ NZ727996A patent/NZ727996A/en unknown
- 2015-07-22 CN CN201580041342.0A patent/CN106573939B/zh active Active
- 2015-07-22 KR KR1020177005142A patent/KR102460181B1/ko active IP Right Grant
- 2015-07-22 EP EP22154464.6A patent/EP4023650A1/en active Pending
- 2015-07-22 BR BR112017001565A patent/BR112017001565A2/pt not_active IP Right Cessation
-
2016
- 2016-12-21 IL IL249706A patent/IL249706A0/en unknown
-
2017
- 2017-09-27 US US15/717,493 patent/US10179794B2/en active Active
-
2018
- 2018-11-28 US US16/203,112 patent/US10501476B2/en active Active
-
2019
- 2019-11-25 JP JP2019212344A patent/JP6991188B2/ja active Active
-
2021
- 2021-11-08 JP JP2021181870A patent/JP2022010149A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101280A1 (es) | Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial | |
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| AR100160A1 (es) | 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| AR094174A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR090955A1 (es) | Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| EA201691775A1 (ru) | Производные 1,2-дигидро-3н-пирроло[1,2-с]имидазол-3-она и их применение в качестве антибактериальных средств | |
| EA201890626A1 (ru) | ЗАМЕЩЕННЫЕ 1,2-ДИГИДРО-3H-ПИРРОЛО[1,2-c]ИМИДАЗОЛ-3-ОНОВЫЕ АНТИБАКТЕРИАЛЬНЫЕ СОЕДИНЕНИЯ | |
| AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
| AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |